| Title |
Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2
|
|---|---|
| Published in |
bioRxiv, October 2020
|
| DOI | 10.1101/2020.10.29.352450 |
| Authors |
Allison Bakovic, Kenneth Risner, Nishank Bhalla, Farhang Alem, Theresa L. Chang, Warren Weston, Jane A. Harness, Aarthi Narayanan |
X Demographics
The data shown below were collected from the profiles of 28 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 7 | 25% |
| United Kingdom | 2 | 7% |
| Canada | 1 | 4% |
| Belgium | 1 | 4% |
| Iceland | 1 | 4% |
| Libya | 1 | 4% |
| India | 1 | 4% |
| Unknown | 14 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 26 | 93% |
| Practitioners (doctors, other healthcare professionals) | 1 | 4% |
| Scientists | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 20 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 5 | 25% |
| Student > Ph. D. Student | 4 | 20% |
| Researcher | 4 | 20% |
| Student > Doctoral Student | 2 | 10% |
| Student > Master | 2 | 10% |
| Other | 2 | 10% |
| Unknown | 1 | 5% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 15% |
| Biochemistry, Genetics and Molecular Biology | 3 | 15% |
| Immunology and Microbiology | 2 | 10% |
| Chemistry | 2 | 10% |
| Nursing and Health Professions | 1 | 5% |
| Other | 6 | 30% |
| Unknown | 3 | 15% |